{"slug":"retatrutide","title":"Retatrutide","body":"Retatrutide is an investigational once-weekly injection from Eli Lilly that hits three hormone receptors at once — GLP-1, GIP, and glucagon. In its Phase 2 obesity trial the top dose produced a 24.2% average weight loss at 48 weeks, the largest ever reported for a drug alone, and the curve had not flattened. It is the newest and strongest member of the incretin class, it is not approved or for sale anywhere yet, and it keeps appearing in conversations about spinal discs for one concrete reason: body weight is a load a disc has to carry, and Lilly is already trialing this drug for knee osteoarthritis, sleep apnea, and — directly relevant — chronic low back pain. This page is the full picture: the three-receptor mechanism, the exact efficacy and dosing, the adverse events with real numbers, the striking liver-fat data, how it compares to semaglutide and tirzepatide, the muscle-loss question, and the honest version of the spine argument. Zero prior knowledge assumed.\n\n## Three receptors, one bet\n\nTirzepatide already showed what happens when you agonize GLP-1 and GIP together: appetite falls, the stomach empties slower, people eat less. Retatrutide adds the glucagon receptor, which does the opposite of what a diabetes-adjacent drug \"should\" — it raises energy expenditure and pushes the liver to burn fat. So the molecule works both ends at once: less energy in, more energy out, from one weekly shot. A 2025 review called it, without much hedging, a game-changer in obesity pharmacotherapy.\n\n[[embed:source:s5]]\n\nThe glucagon arm is also the double-edged part. It is what makes retatrutide potentially stronger on fat loss, and it is the receptor that most demands the careful Phase 3 safety read — glucagon nudges heart rate and glucose output — which is part of why the program is so large.\n\n## The number that got everyone's attention\n\nThe Phase 2 obesity trial ran 48 weeks. Least-squares mean weight change by dose: −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% at 12 mg. At that top dose, everyone lost at least 5%, 93% lost ≥10%, 83% lost ≥15%, about half lost ≥25%, and a quarter lost ≥30%. Critically, the trajectory had not plateaued at 48 weeks — implying more loss with longer treatment, which Phase 3 later bore out (~28% at 80 weeks).\n\n[[embed:source:s4]]\n\nIt is disproportionately fat, too: a body-composition substudy in type 2 diabetes found retatrutide cut total fat mass more than both placebo and dulaglutide.\n\n[[embed:source:s6]]\n\n## The liver result is the quiet headline\n\nThe effect on liver fat is arguably more striking than the scale number. In the Phase 2a MASLD substudy, relative liver-fat reduction at 48 weeks reached −86.0% at 12 mg, and 93% of those patients dropped to a normal liver-fat level (under 5%) versus zero on placebo. Hepatologists called it among the most potent pharmacologic liver-fat reductions ever reported — credited to the glucagon arm — and it drove a dedicated Phase 3 MASH program with biopsy endpoints.\n\n## How it's dosed, and why the ramp is slow\n\nRetatrutide is a subcutaneous injection once weekly (half-life ~6 days). Dosing is titrated up over months: start at 2 or 4 mg, escalate every four weeks. That slow ramp is not marketing — the adverse events cluster during escalation, and a lower 2 mg start measurably reduced them. Going too fast is how people get the GI effects that make them quit.\n\n## The adverse events, with real numbers\n\nThe profile is the incretin-class one, dose-dependent, mostly during escalation. At 12 mg: nausea 45%, decreased appetite 29%, vomiting 19%, constipation 16%, diarrhea 15%, fatigue 10% (placebo nausea was 11%). Discontinuation for adverse events ran 6-16% versus 0% on placebo. Two glucagon-specific notes: heart rate rose dose-dependently, peaking around week 24 then declining, and despite glucagon's tendency to raise blood sugar there was no clinically significant hypoglycemia — glycemic control actually improved, with 72% of prediabetic participants returning to normal. One odder signal: cutaneous hyperesthesia (skin sensitivity) in 7% versus 1% on placebo, all mild. One acute pancreatitis case; transient liver-enzyme rise in 1%.\n\n[[embed:source:s1]]\n\n## How it stacks up against what's already out\n\nThe ranking tracks the receptor count. Semaglutide (one receptor, GLP-1) delivers about 15% weight loss in its obesity trial; tirzepatide (two, GLP-1/GIP) about 16-22.5%; retatrutide (three) 24.2% at 48 weeks and still falling, rising toward ~28% in Phase 3. One receptor, two, three.\n\n[[embed:source:s3]]\n\nThe honest caveat: these are cross-trial comparisons of different durations and populations, not head-to-head. No completed head-to-head retatrutide-versus-tirzepatide obesity trial exists yet. And retatrutide is the least mature — semaglutide and tirzepatide are approved and in millions of people; retatrutide is not.\n\n## The muscle-loss question\n\nEvery incretin drug raises it: roughly 25-40% of the weight lost across the class is lean mass, which matters for strength and for older patients. Retatrutide's body-composition data is relatively reassuring on the ratio (loss skewed to fat, comparable to the class), but because it produces the largest absolute weight loss, the absolute lean-tissue loss can still be substantial. The practical implication is the same one that matters for a spine: resistance training and adequate protein are not optional add-ons.\n\n## Why a weight-loss drug belongs in a disc article\n\nA herniated or degenerating lumbar disc is, mechanically, a load problem. Body weight feeds that load, and the epidemiology is causal, not just correlational: Mendelian-randomization work finds higher BMI raises the odds of disc degeneration, low back pain, and sciatica.\n\nOne caution repeated everywhere as fact: the \"1 lb of body weight equals 4 lb off the spine\" line is catchier than it is proven. The real 4-to-5-fold load spikes measured inside living discs come from bending and lifting — the lever arm of the trunk — not a clean body-weight multiplier. The honest claim is simpler: less body weight, less to multiply every time you bend.\n\nThat the disc angle isn't hand-waving is shown by Lilly's own program. Retatrutide is in Phase 3 not only for obesity but for knee osteoarthritis and obstructive sleep apnea — a weight-bearing joint and a mechanical airway problem — on the theory that treating the adiposity treats the complication.\n\n[[embed:source:s8]]\n\nAnd the most direct signal of all: there is a Phase 3 trial of retatrutide in chronic low back pain, expected to report in 2026. That is the closest any drug in this stack comes to a real spine trial — and it is a weight/load drug, not a disc-repair one.\n\n## Where the evidence still stops\n\nThere is no long-term human safety record yet, no approval, and the first Phase 3 readouts (type 2 diabetes) are only now landing.\n\n[[embed:source:s7]]\n\nBecause no product exists, unregulated \"research chemical\" retatrutide is sold online with no guarantee of identity, dose accuracy, or sterility — and self-titration bypasses the slow escalation that controls the GI toxicity and the glucagon-driven heart-rate effect. The disc case remains inference: weight reduction plus an adjacent knee-OA trial and a not-yet-reported back-pain trial, not a disc-repair finding.\n\n## Proven, unproven, unknown\n\nProven: retatrutide produces the largest weight loss and one of the largest liver-fat reductions of any drug studied, in randomized trials, with a dose-dependent GI-and-heart-rate profile. Unproven: that it does anything for a disc beyond removing load — and even the load-to-disc benefit is inference until the low-back-pain trial reads out. Unknown: long-term safety, and whether unregulated sourcing delivers the real molecule at the stated dose.\n\n*Not medical advice. Retatrutide is investigational and not approved for weight loss or any disc condition. Nothing here is a dosing or treatment recommendation.*\n","register":"essay","tags":["peptide","retatrutide","glp-1","obesity","disc"],"category":null,"style":{"register":"standard"},"claims":[{"id":"rc-mech","text":"Retatrutide is a single synthetic peptide that agonizes three receptors at once — GLP-1, GIP, and glucagon (GCGR).","tier":"mechanistic","source_ids":["s8"],"why_material":"Defines what the compound is and why it differs from dual agonists."},{"id":"rc-mech2","text":"Glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation, adding an energy-output arm on top of the appetite-suppressing GLP-1/GIP arms.","tier":"mechanistic","source_ids":["s5"],"why_material":"Explains the mechanistic rationale for the third receptor."},{"id":"rc-obesity","text":"In adults with obesity, meta-analysis finds retatrutide produces large, dose-dependent body-weight reductions, statistically and clinically superior to placebo, with the highest doses approaching ~24% at ~48 weeks.","tier":"human","source_ids":["s3","s4"],"why_material":"The headline efficacy claim, graded to pooled human data."},{"id":"rc-t2d","text":"In type 2 diabetes, a Phase 2 substudy found retatrutide significantly improved total body-fat-mass reduction versus both placebo and dulaglutide.","tier":"human","source_ids":["s6"],"why_material":"Efficacy beyond obesity, in a controlled comparison."},{"id":"rc-safety","text":"Adverse events are the dose-dependent incretin profile — nausea, diarrhea, vomiting; a safety review found the profile acceptable but did not establish long-term safety.","tier":"human","source_ids":["s2","s4"],"why_material":"Names the known harms and their dependence on dose."},{"id":"rc-phase3","text":"The Phase 3 TRIUMPH program is ongoing and retatrutide is not approved by any regulator as of writing; everything here is investigational trial data.","tier":"system","source_ids":["s8","s7"],"why_material":"Bounds the evidence — no approval, no completed Phase 3."},{"id":"rc-ruo","text":"This is a research-use-only compound. The article reports trial data; it is not medical advice and does not establish a treatment for any person.","tier":"system","source_ids":[],"why_material":"Compliance and reader-safety boundary."}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","summary":"2026 Lancet phase 3 trial (TRANSCEND-T2D-1) on retatrutide efficacy/safety in T2D patients.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40728138/","title":"Efficacy and safety of retatrutide for the treatment of obesity","quote":"This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data.","summary":"2025 systematic review on retatrutide safety/efficacy for obesity.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes.","summary":"2025 meta-analysis showing retatrutide superior to placebo for obesity.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"2025 meta-analysis on retatrutide for obesity treatment.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile.","summary":"2025 review on retatrutide mechanisms, efficacy, and safety.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"2025 phase 2 substudy on retatrutide effects on body composition in T2D.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s7","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease.","summary":"Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity-related disease states.","summary":"Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s9","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.","author":"","publisher":"","date":"","claim_ids":[]},{"id":"s10","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.","author":"","publisher":"","date":"","claim_ids":[]}],"prov":{"model":"Fable 5 (Claude Code)","action":"write"}}